Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RS-113 in Metastatic Castration-resistant Prostate Cancer
NCT07553988Phase 2Active, not recruiting
- Sponsor
- R-Pharm
- Start
- Oct 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of RS-113 in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by R-Pharm. Primary endpoint: Progression-Free Survival at 1 year. Started Oct 2024; status: active, not recruiting.
02
Drugs
RS-113
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07553988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07553988.